乳腺癌中的免疫检查点抑制:针对PD-1/PD-L1通路进行治疗进展
Yunjin Shin1, Kibeom Shin1, Sihyeon Lee1
1Department of Biotechnology and Bioscience, Sejong University, Seoul, Korea.
Breast cancer (Tokyo, Japan)
|October 22, 2025
概括
针对PD-1/PD-L1轴的免疫检查点抑制剂在治疗乳腺癌,特别是三阴性乳腺癌 (TNBC) 中表现有前途. 临床试验表明,这些新型疗法改善了无进展生存率和病理完整反应率.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 乳腺癌 (BC) 是女性常见的免疫原性恶性瘤.
- 瘤利用编程细胞死亡蛋白1 (PD-1) 和其连接体PD-L1免疫检查点来逃避免疫检测.
- 免疫检查点抑制剂 (ICI) 是一个有前途的治疗策略,特别是在三阴性乳腺癌 (TNBC) 中.
研究的目的:
- 审查乳腺癌中的PD-1/PD-L1通路.
- 总结ICI在BC治疗中的治疗影响和临床进展.
- 探索ICI在乳腺癌管理中的未来潜力.
主要方法:
- 临床试验和研究对乳腺癌中PD-1/PD-L1通路抑制剂的文献综述.
- 从IMpassion130和KEYNOTE-522.22等关键试验的数据分析.
- 综合关于ICI在BC中的作用机制,疗效和安全性的信息.
主要成果:
- IMpassion130试验显示,阿特佐利祖马布加纳布-帕克利塔塞尔在BC患者中改善了无进展生存期 (PFS).
- 在KEYNOTE-522试验报告了更高的病理完整响应 (pCR) 率与pembrolizumab-化疗与单独化疗.
- 针对PD-1/PD-L1轴的ICI治疗在特定的乳腺癌亚型中显示出显著的临床益处.
结论:
- PD-1/PD-L1通路是乳腺癌免疫治疗的关键目标.
- ICI已经证明在改善患者结局方面具有有效性,特别是在TNBC中.
- 需要进一步的研究和临床试验,以优化ICI在多种BC人群中的使用.
更多相关视频
06:07Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
6.1K
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
1.7K
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
The Intrinsic Apoptotic Pathway
8.3K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.3K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
